AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...

Mental Health Medications: How Do They Work? There are several types of drugs available to treat mental illnesses. Some of the most commonly used are antidepressants, anti-anxiety drugs ...

If you have high blood pressure, medication may be an important part of the plan to keep you healthy. Also called antihypertensive medicines, these drugs can't cure high blood pressure but can ...

AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's ...

AbbVie Inc. ABBV reported fourth-quarter 2024 ... Revenues in the fourth quarter were driven by robust sales of key drugs Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant ...

AbbVie’s oncology/hematology sales rose 12.9% to $1.69 billion in the quarter, as sales from the recently acquired ovarian cancer drug Elahere and rising Venclexta sales more than offset the ...